P/B
8,6
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
$4.6B
Market Cap • 10/9/2026
2016
(10 years)
Founded
2025
(1 year ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
11,6
P/EBITDA
92,1
P/OCF
102,1
P/FCF
139,5
P/E
140,1
BVPS
11,4
EPS
0,7
Market Cap
Market Cap
4,6B
EV
4,2B
EV/Revenue
10,6
EV/EBITDA
84,1
EV/EBIT
97,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-6,5%
Total Yield
-6,5%
Payout
0%
Retained Earnings
-248,7M
Profitability
Gross Margin
71,3%
EBITDA Margin
12,6%
EBIT Margin
10,9%
Net Margin
9,6%
D&A/EBITDA
0%
R&D/Revenue
14,9%
Capex/Revenue
3,1%
Capex/D&A
175,6%
Capex/OCF
26,9%
SBC/OCF
56,3%
% PPE
10%
% Goodwill
0%
ROE
10,8%
ROIC
39,1%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
11,3
Quick Ratio
11,2
Interest Coverage
105615%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!